Monthly
US$200
Billed every month
Sign in to subscribeDiquafosol Sodium Eye Drops
As of 13 November 2026, for Diquafosol Sodium Eye Drops, 5 applications are listed as under review at China's CDE; 3 companies have filed new generic applications in 2026; the chemical-drug catalogue lists 1 holder.
Companies, stages and changes, with each record available on this page.
Last 90 days: Accepted: 2 applicationsNo longer listed under review: 1 application
Current coverage may be incomplete
Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.
Catalogue holders1View records ↓
Under-review filings5View records ↓
This year’s generic filers3View records ↓
NHSA approval numbers63View records ↓
API companies with A status14View records ↓
Chemical-drug catalogue
Loaded records: 1 holders; 0 in the quality-and-efficacy consistency-evaluation category, and 0 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| Santen Pharmaceutical Co.,Ltd. | Santen Pharmaceutical Co.,Ltd.Noto Plant | H20181012 | 2017/10/20 | 3%（5ml:150mg） | Imported originator drug | CDE |
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 63 distinct approval numbers and 52 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| Guangdong Nan Guo Pharma Co., Ltd. romanized | 国药准字H20264803 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010100315 | NHSA |
| Guangdong Zhong Sheng Pharma Co., Ltd. romanized | 国药准字H20233141 | 3%(5ml∶150mg) | Not stated by source | XS01XAD324G010010100371 | NHSA |
| Shenzhen Shi Hua Sheng Yuan Ji Yin Gong Cheng Development Co., Ltd. romanized | 国药准字H20254149 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010010100528 | NHSA |
| Shenzhen Wan He Pharmaceutical Co., Ltd. romanized | 国药准字H20243354 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010100547 | NHSA |
| Guangzhou Da Guang Pharmaceutical Co., Ltd. romanized | 国药准字H20255054 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010010100548 | NHSA |
| Zhuhai Yi Sheng Biopharmaceutical Co., Ltd. romanized | 国药准字H20244650 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010010100612 | NHSA |
| Zhongguo Da Zhong Pharmaceutical Co., Ltd. romanized | 国药准字H20255318 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010010100967 | NHSA |
| Shenyang Xing Qi Yan Yao Co., Ltd. romanized | 国药准字H20233992 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010101322 | NHSA |
| Jiangsu Fu Bang Pharma Co., Ltd. romanized | 国药准字H20255901 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010101438 | NHSA |
| Jiangsu Vanguard Pharmaceutical Co., Ltd. | 国药准字H20243334 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010101503 | NHSA |
| Suzhou Le Zhu Pharmaceutical Co., Ltd. romanized | 国药准字H20249361 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010101652 | NHSA |
| Yangtze River Pharmaceutical Group Co., Ltd | 国药准字H20223580 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010101749 | NHSA |
| Jiangsu Heng Xin Pharma Co., Ltd. romanized | 国药准字H20244672 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010101765 | NHSA |
| Hubei Yuan Da Tian Tian Ming Pharmaceutical Co., Ltd. romanized | 国药准字H20243571 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010101967 | NHSA |
| Wuhan Wu Jing Pharma Co., Ltd. romanized | 国药准字H20253766 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010101978 | NHSA |
| Sichuan Mei Da Kang Hua Kang Pharma Co., Ltd. romanized | 国药准字H20255135 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010102087 | NHSA |
| Chengdu Pusch Pharmaceutical Co., Ltd. | 国药准字H20243167 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010010102298 | NHSA |
| Shaanxi Bo Sen Biopharmaceutical Shareholding Group Co., Ltd. romanized | 国药准字H20244361 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010102357 | NHSA |
| Shijiazhuang Gree Pharmaceutical Co., Ltd | 国药准字H20253908 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010102733 | NHSA |
| Le Pu Pharma Co., Ltd. romanized | 国药准字H20244890 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010010103094 | NHSA |
| Qilu Pharmaceutical Co., Ltd. | 国药准字H20223344 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010010104021 | NHSA |
| Shandong Hai Shan Pharma Co., Ltd. romanized | 国药准字H20254031 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010104094 | NHSA |
| Shandong Chen Xin Fu Dou Pharma Co., Ltd. romanized | 国药准字H20243358 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010104127 | NHSA |
| Hangzhou Guo Guang Pharma Co., Ltd. romanized | 国药准字H20243119 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010104478 | NHSA |
| Fujian Bo Yue Pharmaceuticals Technology Co., Ltd. romanized | 国药准字H20255222 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010104494 | NHSA |
| Zhejiang Jian Feng Pharma Co., Ltd. romanized | 国药准字H20249603 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010104655 | NHSA |
| Zhejiang Sha Pu Ai Si Pharma Co., Ltd. romanized | 国药准字H20244731 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010010104693 | NHSA |
| Zhuhai Qian Lie Pharma Co., Ltd. romanized | 国药准字H20253203 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010104929 | NHSA |
| Jiangxi Ma Ying Long Mei Kang Pharma Co., Ltd. romanized | 国药准字H20244360 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010105293 | NHSA |
| Zhen Shi Ming (Jiangxi) Pharma Co., Ltd. romanized | 国药准字H20244250 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010105387 | NHSA |
| Jiangsu Yuan Heng Pharma Co., Ltd. romanized | 国药准字H20249234 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010106033 | NHSA |
| Santen Pharmaceutical Co., Ltd. | 国药准字J20180008 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010109591 | NHSA |
| Zhongshan Wanhan Pharmaceuticals Co., Ltd. | 国药准字H20244720 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010010109920 | NHSA |
| Santen Pharmaceutical Co.,Ltd. | 国药准字HJ20181012 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010178986 | NHSA |
| Zhengzhou Zhuo Feng Pharmaceutical Co., Ltd. romanized | 国药准字H20254146 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010179276 | NHSA |
| Chengdu Sheng Di Pharmaceuticals Co., Ltd. romanized | 国药准字H20223336 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010180435 | NHSA |
| Shandong Shen Lian Pharma Co., Ltd. romanized | 国药准字H20253182 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010010180461 | NHSA |
| Sichuan He Yi Pharmaceutical Co., Ltd. romanized | 国药准字H20244084 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010010181567 | NHSA |
| Hua Run Zi Zhu Pharma Co., Ltd. romanized | 国药准字H20243438 | 3%(0.4ml∶12mg) | Not stated by source | XS01XAD324G010010183035 | NHSA |
| Beijing Nuo Si Lan De Bio Technology Co., Ltd. romanized | 国药准字H20234037 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010183060 | NHSA |
| Shandong Bo Shi Lun Fu Rui Da Pharmaceutical Co., Ltd. romanized | 国药准字H20255902 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010183223 | NHSA |
| Suzhou Lang Ke Bio Technology Co., Ltd. romanized | 国药准字H20254814 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010183485 | NHSA |
| Suzhou Ou Kang Wei Shi Bio Technology Co., Ltd. romanized | 国药准字H20244235 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010183562 | NHSA |
| Jiangsu Guang Cheng Pharma Co., Ltd. romanized | 国药准字H20263726 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010183611 | NHSA |
| Shenzhen Shi Yu Jian Biopharmaceuticals Co., Ltd. romanized | 国药准字H20263224 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010183757 | NHSA |
| Heilongjiang Sheng Zhi Run Pharma Co., Ltd. romanized | 国药准字H20244800 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010183931 | NHSA |
| Wuhan Xian Lu Pharmaceuticals Technology Co., Ltd. romanized | 国药准字H20255425 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010010184190 | NHSA |
| Nanjing Huang Long Bio Technology Co., Ltd. romanized | 国药准字H20249182 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010184437 | NHSA |
| Nanjing Hua Xing Pharmaceuticals Technology Co., Ltd. romanized | 国药准字H20253205 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010184657 | NHSA |
| Run Er Yan Ke Drug (Guangzhou) Co., Ltd. romanized | 国药准字H20244698 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010184784 | NHSA |
| Zhengzhou Wei Xian Pharmaceuticals Technology Co., Ltd. romanized | 国药准字H20253918 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010010185259 | NHSA |
| You Hua Pharmaceuticals Technology Co., Ltd. romanized | 国药准字H20253859 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010185280 | NHSA |
| Guangzhou Da Guang Pharmaceutical Co., Ltd. romanized | 国药准字H20255054 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010010200548 | NHSA |
| Zhuhai Yi Sheng Biopharmaceutical Co., Ltd. romanized | 国药准字H20244650 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010010200612 | NHSA |
| Chengdu Pusch Pharmaceutical Co., Ltd. | 国药准字H20243167 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010010202298 | NHSA |
| Le Pu Pharma Co., Ltd. romanized | 国药准字H20244890 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010010203094 | NHSA |
| Shandong Chen Xin Fu Dou Pharma Co., Ltd. romanized | 国药准字H20243358 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010204127 | NHSA |
| Zhongshan Wanhan Pharmaceuticals Co., Ltd. | 国药准字H20244720 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010010209920 | NHSA |
| Santen Pharmaceutical Co., Ltd. | 国药准字HJ20170378 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010278986 | NHSA |
| Sichuan He Yi Pharmaceutical Co., Ltd. romanized | 国药准字H20244084 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010010281567 | NHSA |
| Chengdu Pusch Pharmaceutical Co., Ltd. | 国药准字H20243167 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010010302298 | NHSA |
| Le Pu Pharma Co., Ltd. romanized | 国药准字H20244890 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010010303094 | NHSA |
| Shandong Chen Xin Fu Dou Pharma Co., Ltd. romanized | 国药准字H20243358 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010010304127 | NHSA |
| Sichuan He Yi Pharmaceutical Co., Ltd. romanized | 国药准字H20244084 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010010381567 | NHSA |
| Chengdu Pusch Pharmaceutical Co., Ltd. | 国药准字H20243167 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010010402298 | NHSA |
| Le Pu Pharma Co., Ltd. romanized | 国药准字H20244890 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010010403094 | NHSA |
| Sichuan He Yi Pharmaceutical Co., Ltd. romanized | 国药准字H20244084 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010010481567 | NHSA |
| Le Pu Pharma Co., Ltd. romanized | 国药准字H20244890 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010010503094 | NHSA |
| Sichuan He Yi Pharmaceutical Co., Ltd. romanized | 国药准字H20244084 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010010581567 | NHSA |
| Le Pu Pharma Co., Ltd. romanized | 国药准字H20244890 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010010603094 | NHSA |
| Sichuan He Yi Pharmaceutical Co., Ltd. romanized | 国药准字H20244084 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010010681567 | NHSA |
| Sichuan He Yi Pharmaceutical Co., Ltd. romanized | 国药准字H20244084 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010010781567 | NHSA |
| Sichuan He Yi Pharmaceutical Co., Ltd. romanized | 国药准字H20244084 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010010881567 | NHSA |
| Guangzhou Da Guang Pharmaceutical Co., Ltd. romanized | 国药准字H20255055 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010020100548 | NHSA |
| Jiangsu Fu Bang Pharma Co., Ltd. romanized | 国药准字H20263729 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010020101438 | NHSA |
| Chengdu Pusch Pharmaceutical Co., Ltd. | 国药准字H20258188 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010020102298 | NHSA |
| Shijiazhuang Gree Pharmaceutical Co., Ltd | 国药准字H20253907 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010020102733 | NHSA |
| Qilu Pharmaceutical Co., Ltd. | 国药准字H20233191 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010020104021 | NHSA |
| Zhuhai Qian Lie Pharma Co., Ltd. romanized | 国药准字H20253202 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010020104929 | NHSA |
| Zhongshan Wanhan Pharmaceuticals Co., Ltd. | 国药准字H20244719 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010020109920 | NHSA |
| Chengdu Sheng Di Pharmaceuticals Co., Ltd. romanized | 国药准字H20234117 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010020180435 | NHSA |
| Zhengzhou Wei Xian Pharmaceuticals Technology Co., Ltd. romanized | 国药准字H20253919 | 3%(5ml:150mg) | Not stated by source | XS01XAD324G010020185259 | NHSA |
| Jiangsu Fu Bang Pharma Co., Ltd. romanized | 国药准字H20263729 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010020201438 | NHSA |
| Shijiazhuang Gree Pharmaceutical Co., Ltd | 国药准字H20253907 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010020202733 | NHSA |
| Chengdu Sheng Di Pharmaceuticals Co., Ltd. romanized | 国药准字H20234117 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010020280435 | NHSA |
| Chengdu Sheng Di Pharmaceuticals Co., Ltd. romanized | 国药准字H20234117 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010020380435 | NHSA |
| Chengdu Sheng Di Pharmaceuticals Co., Ltd. romanized | 国药准字H20234117 | 3%(0.4ml:12mg) | Not stated by source | XS01XAD324G010020480435 | NHSA |
| Shandong Hua Bo Kai Sheng Bio Technology Co., Ltd. romanized | 国药准字H20266157 | 3%(5ml∶150mg) | Not stated by source | XS01XAD324G010010183034 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 5 filings and 4 distinct first applicants.
Import re-registration 2 · Generic 3
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| Santen Pharmaceutical Co. Ltd.; Santen Pharmaceutical Co. Ltd. Noto Plant | JYHZ2600215 | Import re-registration | 2026/09/03 | Not stated by source | CDE |
| Santen Pharmaceutical Co. Ltd.; Santen Pharmaceutical Co. Ltd. Noto Plant | JYHZ2600214 | Import re-registration | 2026/09/03 | Not stated by source | CDE |
| Xiu Zheng Pharma Group Changchun Gao Xin Pharmaceutical Co., Ltd. romanized | CYHS2601847 | Generic | 2026/07/31 | Not stated by source | CDE |
| Hubei Kang Zheng Pharma Co., Ltd. romanized | CYHS2601139 | Generic | 2026/05/14 | Not stated by source | CDE |
| Sichuan Hao Yi Sheng Pan Xi Pharma Co., Ltd. romanized; Hefei Hua Wei Pharma Co., Ltd. romanized | CYHS2600543 | Generic | 2026/02/26 | Not stated by source | CDE |
New generic filings in 2026
Loaded records: 3 filings and 3 distinct first applicants.
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| Xiu Zheng Pharma Group Changchun Gao Xin Pharmaceutical Co., Ltd. romanized | CYHS2601847 | Generic | 2026/07/31 | Not stated by source | CDE |
| Hubei Kang Zheng Pharma Co., Ltd. romanized | CYHS2601139 | Generic | 2026/05/14 | Not stated by source | CDE |
| Sichuan Hao Yi Sheng Pan Xi Pharma Co., Ltd. romanized; Hefei Hua Wei Pharma Co., Ltd. romanized | CYHS2600543 | Generic | 2026/02/26 | Not stated by source | CDE |
API registrations
Non-component matches: 14 companies with A status and 1 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| 地夸磷索钠 · No verified English name | YAMASA CORPORATION | Y20240001320 | A | Exact ingredient | 2026/10/21 | CDE |
| 地夸磷索钠 · No verified English name | Yang Zhou Shi San Yao Pharmaceutical Co., Ltd. romanized | Y20240001036 | A | Exact ingredient | 2026/04/01 | CDE |
| 地夸磷索钠 · No verified English name | Zhejiang Hai Xiang Pharma Co., Ltd. romanized | Y20240000710 | A | Exact ingredient | 2026/05/20 | CDE |
| 地夸磷索钠 · No verified English name | Yang Zhou Shi San Yao Pharmaceutical Co., Ltd. romanized | Y20230001112 | I | Exact ingredient | 2024/09/25 | CDE |
| 地夸磷索钠 · No verified English name | Zhejiang Hua Na Pharma Co., Ltd. romanized | Y20230000950 | A | Exact ingredient | 2026/05/20 | CDE |
| 地夸磷索钠 · No verified English name | Hunan Hua Na Da Pharmaceutical Factory Shou Xing Drug Co., Ltd. romanized | Y20230000327 | A | Exact ingredient | 2026/06/02 | CDE |
| 地夸磷索钠 · No verified English name | Guangdong Xian Qiang Pharma Co., Ltd. romanized | Y20220000671 | A | Exact ingredient | 2025/02/07 | CDE |
| 地夸磷索钠 · No verified English name | Changzhou Hong Tai Yang Pharma Co., Ltd. romanized | Y20220000502 | A | Exact ingredient | 2024/06/21 | CDE |
| 地夸磷索钠 · No verified English name | Fujian Nan Fang Pharmaceutical Co., Ltd. romanized | Y20220000228 | A | Exact ingredient | 2024/12/31 | CDE |
| 地夸磷索钠 · No verified English name | CKD Bio Corporation | Y20210000722 | A | Exact ingredient | 2023/09/07 | CDE |
| 地夸磷索钠 · No verified English name | Suzhou Di Si Pharmaceutical Factory Co., Ltd. romanized | Y20210000612 | A | Exact ingredient | 2023/06/21 | CDE |
| 地夸磷索钠 · No verified English name | Kyongbo Pharmaceutical Co., Ltd. | Y20210000404 | A | Exact ingredient | 2023/07/28 | CDE |
| 地夸磷索钠 · No verified English name | Yang Zi Jiang Pharma Group Jiangsu Hai Ci Bio Pharma Co., Ltd. romanized | Y20200001400 | A | Exact ingredient | 2026/05/20 | CDE |
| 地夸磷索钠 · No verified English name | Qilu Pharmaceutical Co., Ltd. | Y20200001210 | A | Exact ingredient | 2023/06/30 | CDE |
| 地夸磷索钠 · No verified English name | Guangdong Xian Qiang Pharma Co., Ltd. romanized | Y20200000651 | A | Exact ingredient | 2023/03/24 | CDE |
| 地夸磷索钠 · No verified English name | Chengdu Xin Yue Pharmaceuticals Co., Ltd. romanized | Y20200000550 | A | Exact ingredient | 2023/03/24 | CDE |
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/13 06:39. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
This source was last successfully updated at 2026/11/12 18:32; current coverage may be incomplete.
-
2026/11/03No longer listed under review
Hainan Si Da Pharmaceutical Co., Ltd. romanized
CYHS2501887
Fact date: 2026/11/03 · Site observation date: 2026/11/03
Accepted: 2025/05/27
not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked
View source ↗ -
2026/09/03Accepted
Santen Pharmaceutical Co. Ltd.; Santen Pharmaceutical Co. Ltd. Noto Plant
JYHZ2600215
Fact date: 2026/09/03 · Site observation date: 2026/10/22
View source ↗ -
2026/09/03Accepted
Santen Pharmaceutical Co. Ltd.; Santen Pharmaceutical Co. Ltd. Noto Plant
JYHZ2600214
Fact date: 2026/09/03 · Site observation date: 2026/10/22
View source ↗
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/13 06:42
- Chemical-drug catalogue
- Last successful update: 2026/11/13 06:39
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/13 06:41
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/12 18:32 · Current coverage may be incomplete
First index-page publication dates: 2026-10-29 to 2026-11-13; 2 pages pending. Covers loaded notices only, not a complete historical approval database.
- Drug Clinical Trial Registry and Information Disclosure Platform
- Last successful update: 2026/11/13 08:09 · Current coverage may be incomplete
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 7/30; discovered pending details: 13. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to Diquafosol Sodium Eye Drops
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Sign in to subscribeYearly
US$1,920
Billed every year
US$160 per month
Sign in to subscribeNeed more than 10 followed products or more than 5 recipients? Contact us.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
Billed by Creem, our merchant of record · Terms · Refund policy